Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 168

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 168
---
b) up to an aggregate of $540 million upon the achievement of certain commercial milestones, in each case, across all ADC Programs. WuXi Biologics is also
entitled to running royalties during the agreed upon royalty term ranging from low-single-digit to upper-single-digit percentages of annual net sales of licensed products.

Pursuant to the terms of the License Agreement, to the extent any amounts payable under or in connection with the License Agreement are subject to any
value-added tax or indirect tax, such taxes shall be borne and paid by Aadi. The parties, however, are obligated to cooperate with each other to secure any available exemption or reduction in such taxes as specified in the License Agreement.

- 111 -

Royalty Term

For any licensed product for which we are required to pay WuXi Biologics royalties, we will pay WuXi Biologics royalties on a licensed product-by-licensed product and region-by-region basis until the latest of (i) the
expiration of certain patents covering the relevant licensed product and (ii) an agreed period of time after the first commercial sale of that product in the applicable region. If generic competition occurs or there are no certain patents
covering the applicable antibody drug conjugate included in the licensed product, Aadi’s royalty obligations in the applicable region would be reduced as specified in the License Agreement.

Development, Commercialization and Manufacturing

Under the License Agreement, Aadi is wholly responsible for the development and commercialization of licensed products across all Programs, subject to certain
conditions. We also have sole control, at our expense, over all interactions with regulatory authorities with respect to licensed products.

In addition,
we control the manufacture and supply of licensed products and components thereof. Notwithstanding the foregoing, until such time as we elect to assume control of licensed product manufacturing, WuXi Biologics agreed to, directly or through a
certain affiliate, manufacture and supply our reasonable requirements of licensed product and components thereof pursuant to the terms of a commercially reasonable and mutually acceptable supply agreement to be executed by the parties at a later
date.

Term, Termination and Effects of Termination

If we do not pay WuXi Biologics the second tranche of the upfront payment (i.e., $38 million) within the time period set forth in the License Agreement, the
License Agreement will terminate at the end of such period. If we do pay such amount in accordance with the terms of the License Agreement, the License Agreement will remain in effect until expiration of the last to expire royalty term.